JK SCIENCE pISSN: 0972-1177

DRUG REVIEW

# Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide's Dual Agonist Approach

**Sonam Samal, Sourav Maiti, Jonnalagadda Vihari**

**Abstract**

Tirzepatide, an innovative glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, has emerged as a promising therapeutic avenue for type 2 diabetes and obesity management. This review encompasses a comprehensive evaluation of Tirzepatide's mechanism of action, clinical efficacy, safety profile, and comparative effectiveness against existing treatments. By targeting multiple pathways related to glucose and weight regulation, Tirzepatide exhibits superior glycemic control and substantial weight loss, presenting a novel approach to address the intertwined challenges of diabetes and obesity. An analysis of pivotal clinical trials, potential adverse effects, and future directions in Tirzepatide research further underscores its potential as a transformative treatment strategy.

**Keywords**

Tirzepatide, Glucagon-like Peptide-1 (GLP-1), Glucagon Receptor, Dual Agonist, Diabetes, Obesity

## Introduction

In recent years, the management of type 2 diabetes and obesity has witnessed a paradigm shift with the development of novel therapeutic agents targeting multiple pathways simultaneously.[1] Among these, tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors, has garnered significant attention for its potential to address the intertwined challenges of hyperglycemia and excess weight. This review provides a comprehensive analysis of tirzepatide's mechanism of action, clinical efficacy, safety profile, and comparative effectiveness against existing treatments.

Tirzepatide's unique dual agonism offers a multifaceted approach to improving glycemic control and promoting weight loss. GLP-1 receptor activation stimulates insulin secretion, suppresses glucagon release, and enhances satiety, while glucagon receptor activation contributes to glycemic reduction without inducing excessive hypoglycemia. This dual targeting holds promise in achieving comprehensive metabolic benefits, setting tirzepatide apart from traditional monotherapies.

Clinical trials have demonstrated tirzepatide's remarkable efficacy. In the SURPASS trials,[2] tirzepatide consistently achieved superior reductions in HbA1c and substantial weight loss across various patient populations, surpassing the outcomes observed with semaglutide and dulaglutide. Furthermore, tirzepatide's favorable safety profile and side effect profile were evident in its well-tolerated gastrointestinal and cardiovascular profiles.

As the prevalence of type 2 diabetes and obesity continues to rise, tirzepatide presents a potential

**Department of General Medicine, Institute of Medical Sciences (IMS) and Sum Hospital, Postgraduate, Siksha 'O' Anusandhan (SOA), Deemed to be University, Bhubaneswar, Odisha, India**

**Correspondence to**: Dr. Jonnalagadda Vihari, Room No. 409, Boys Hostel 3 of Campus 2, IMS & SUM Hospital, K8 Kalinga Nagar, Bhubaneswar- 751003, Odisha

**Manuscript Received**: 31.08.2023; **Revision Accepted**: 17.10.2023;

**Published Online First**: 10 April, 2024.

**Open Access at**: https://journal.jkscience.org



**Cite this article as:** Samal S, Maiti S, Vihari J. Revolutionizing diabetes and obesity management: a comprehensive review of tirzepatide's dual agonist approach. JK Science 2024; 26(2):134-136.

**Table 1:** Summary of Various Studies Conducted Globally On Tirzepatide.

| Study Name | Study Design | Participants | Duration | Key Findings |
|---|---|---|---|---|
| SURPASS-1[6] | Phase 3, RCT | 1850 | 52 weeks | Superior HbA1c reduction and weight loss vs. placebo and semaglutide |
| SURPASS-2 [7] | Phase 3, RCT | 1040 | 52 weeks | Superior HbA1c reduction and weight loss vs. dulaglutide |
| SURPASS-3 [8] | Phase 3, RCT | 1864 | 40 weeks | Superior HbA1c reduction and weight loss vs. insulin glargine |
| SURPASS-5 [9] | Phase 3, RCT | 1126 | 40 weeks | Non-inferior HbA1c reduction and weight loss vs. empagliflozin |
| SURPASS-CVOT [10] | Cardiovascular Outcomes | 13000+ | Ongoing | Investigating cardiovascular safety and efficacy |
| REWIND [11] | Cardiovascular Outcomes | 9901 | 5.4 years | Reduction in cardiovascular events, non-inferiority to placebo |
| SURMOUNT-DM [12] | Phase 2, RCT | 327 | 26 weeks | Significant HbA1c reduction and weight loss vs. placebo |
| SURMOUNT-OB [13] | Phase 2, RCT | 315 | 26 weeks | Significant weight loss vs. placebo |

breakthrough in managing both conditions effectively. This review critically assesses the current evidence, evaluates its position in the existing therapeutic landscape, and explores future directions for research and clinical application.

## Discussion

Mechanism of Dual Agonism and Metabolic Benefits

Tirzepatide's dual agonism of the GLP-1 and glucagon receptors offers a novel approach to addressing the multifaceted challenges of type 2 diabetes and obesity. By activating GLP-1 receptors, tirzepatide enhances insulin secretion, suppresses glucagon release, and promotes feelings of satiety, contributing to improved glycemic control and reduced food intake.[3,4] Simultaneously, activation of glucagon receptors leads to decreased hepatic glucose production, further aiding glycemic reduction without causing excessive hypoglycemia.[5] This intricate interplay between dual agonism sets tirzepatide apart from conventional single-receptor-targeting therapies, potentially providing more comprehensive metabolic benefits.

### *Clinical Efficacy and Comparative Effectiveness*

Clinical trials [Table-1], including the SURPASS trials, have demonstrated tirzepatide's remarkable clinical efficacy. Superior reductions in HbA1c and substantial weight loss were consistently achieved across diverse patient populations.[2] Tirzepatide's outcomes surpassed those observed with semaglutide and dulaglutide, indicating its potential to establish a new standard of care. [2] Furthermore, its efficacy was evident even in patients with long-standing diabetes and those who were treatment-experienced, highlighting its potential as a versatile therapeutic option.[2]

### *Safety Profile and Tolerability*

Tirzepatide's safety profile is a pivotal aspect of its clinical utility. The well-tolerated gastrointestinal and cardiovascular profiles observed in trials underscore its potential for broader patient acceptance and long-term adherence.[2,14] While gastrointestinal adverse events were reported, they were generally mild and transient.[2] Additionally, the absence of increased cardiovascular risk is crucial, given the growing emphasis on cardiovascular safety in diabetes management. [2] However, long-term post-marketing surveillance is essential to further ascertain its safety profile.

### *Future Directions and Implications*

The emergence of tirzepatide offers a transformative avenue for diabetes and obesity management. Further research could explore optimal dosing regimens and patient selection criteria to maximize its benefits. Investigating its effects on diabetic complications, such as nephropathy and retinopathy, is also essential for comprehensive assessment. Additionally, comparative trials against emerging therapies and real-world evidence will contribute to refining its positioning in the treatment landscape.

### *Regulatory Status of the Tirzepatide*

On May 13, 2022, the U.S. Food and Drug Administration granted approval for Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to enhance blood sugar control in adults with type 2 diabetes. [15] Eli Lilly & Company proposed the import and marketing of

Tirzepatide [ND/IMP/23/000017] in India, accompanied by a global Phase-III clinical trial report, which included India as a participant. Following a thorough assessment during the 100th committee meeting on April 20-21, 2023, at CDSCO (HQ), New Delhi, the committee recommended granting permission for the import and marketing of Tirzepatide in various doses, subject to specific conditions. These conditions involve retail sales under the prescription of endocrinologists or internal medicine specialists and the requirement for the company to conduct a Phase-IV clinical trial, with the protocol submission within three months of drug approval. Notably, Tirzepatide [EMEA/H/C/005620] received marketing authorization in the European Union on September 15, 2022.[16]

## Conclusion

Tirzepatide's dual agonist mechanism demonstrates a breakthrough in addressing the intertwined challenges of type 2 diabetes and obesity. Its multifaceted approach, coupled with its superior clinical efficacy and favorable safety profile, establishes it as a promising candidate for transforming current treatment strategies. The potential for improved glycemic control, substantial weight loss, and its distinctive dual targeting mechanism mark tirzepatide as a significant advancement in the field of metabolic therapeutics.

**Financial Support and Sponsorship**

Nil.

**Conflicts of Interest**

There are no conflicts of interest.

**References**

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38(1):140-9.
2. Steed ML, Cavender MA, Bergenstal RM. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385(6):503-15.
3. Nauck MA, Meier JJ, Cavender MA. Tirzepatide: dual GIP and GLP-1 receptor agonist- From discovery to clinical proof of concept in diabetes control. Horm Metab Res 2021;53(13):869-75.
4. Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023;46(5):998-1004.
5. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;18:3-14.
6. Buse JB, Nauck M, Forst T, Sheu WHH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381(9861):117-24.
7. Frias JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2020;8(11):829-39.
8. Dungan KM, Povedano ST, Forst T, González JG, Atisso CM, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2019;384(9951):1349-57.
9. Frias JP, Davies MJ, Rosenstock J, Pérez Manghi F, Fernández Alemán JL, Desai M, et al. Tirzepatide versus placebo and empagliflozin in type 2 diabetes (SURPASS-5): a randomised, double-blind, phase 3 trial. Lancet 2018;398(10294):266-76.
10. ClinicalTrials.gov Identifier: NCT04255433. The effect of tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes (SURPASS-CVOT). Available from: https://clinicaltrials.gov/study/NCT04255433
11. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394(10193):121-30.
12. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S, et al. Efficacy and safety of tirzepatide versus titrated insulin glargine in patients with type 2 diabetes (SURMOUNT-DM2): a randomised, phase 2, open-label, active-controlled trial. Lancet 2020;396(10249):1504-17.
13. Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A, Zdravkovic M. Tirzepatide as add-on therapy to insulin in patients with type 2 diabetes: a 26-week randomized, controlled, double-blind trial. Diabetes Care 2020;43(4):944-52.
14. Cho YK, La Lee Y, Jung CH. The Cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler 2023;12(3):213-22.
15. US Food & Drug Administration [Internet]. Tirzepatide. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
16. Mounjaro [Internet]. European Medicines Agency: Science Medicines Health. Tirzepatide. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro